US EditionSensorion Announces €60 Million Financing With a €20M ...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.9 Articles
9 Articles
pharmaceutical-technology.com
Pharmaceutical Business reviewSensorion announces $71.9m reserved offering to expand gene therapy pipeline
Sensorion has announced a $71.9m reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.
"This is an important step for the growth of society and for patients suffering from various hearing disorders," says Nawal Ouzren, General Manager of Sensorion. "The leader has enough to smile. Sensorion, biotech montpellellierain specializing in hearing disorders, has just raised 60 million euros, per issue of new actions.
Biotech specializing in the treatment of hearing loss raises €60 million, of which €20 million comes from the French pharmaceutical group. Sensorion can now continue its research until June 30, 2027.
Sensorion, specializing in the development of innovative therapies for hearing disorders, announces that it has secured a new funding of €60 million, including a third from the pharmaceutical giant Sanofi. The funds will allow the Montpellieran biotech to support the key steps in its gene therapy pipeline.
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
Sanofi’s investment marks the entry of a strategic shareholder Support from existing investors Redmile Group, Artal, which is advised by Invus, and Sofinnova Partners Participation from leading U.S. Healthcare Specialists funds including Cormorant Asset Management, Coastlands Capital and Sphera Healthcare Cash runway extended until H1 2027, supporting key catalysts including SENS-601 (GJB2-GT) CTA/IND approval and [...] The post Sensorion Announ…
Sensorion raised €60M backed by €20M from Sanofi to advance gene therapies for hearing loss - European Biotechnology Magazine
French biotech company Sensorion announced today a €60 million (about $72 million) reserved offering including a €20 million strategic investment from Sanofi. The remaining €40 million subscribed by existing shareholders Redmile Group, Artal (advised by Invus), and Sofinnova Partners, alongside new investors including Cormorant Asset Management, Coastlands Capital, and Sphera Healthcare, which are leading US Healthcare Specialists funds. The pos…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
